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Abstract
Background: Clinical trials show that asthma can be controlled in the majority of patients, but poorly controlled asthma
still imposes a considerable burden. The level of asthma control achieved reflects the behaviour of both healthcare
professionals and patients. A key challenge for healthcare professionals is to help patients to engage in self-management
behaviours with optimal adherence to appropriate treatment. These issues are particularly relevant in primary care,
where most asthma is managed. An international panel of experts invited by the International Primary Care Respiratory
Group considered the evidence and discussed the implications for primary care practice.
Discussion: Causes of poor control
Clinical factors such as exposure to triggers and concomitant rhinitis are important but so are patient behavioural factors.
Behaviours such as smoking and nonadherence may reduce the efficacy of treatment and patients' perceptions influence
these behaviours. Perceptual barriers to adherence include doubting the need for treatment when symptoms are absent
and concerns about potential adverse effects. Under-treatment may also be related to patients' underestimation of the
significance of symptoms, and lack of awareness of achievable control.
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Implications
Three key implications for healthcare professionals emerged from the debate. First, the need for simple tools to assess
asthma control. Two approaches considered were the monitoring of biometric markers of control and questionnaires
to record patient-reported outcomes. Second, to understand the reasons for poor control for individual patients,
identifying both clinical (e.g. rhinitis) and behavioural factors (e.g. smoking and nonadherence to treatment). Third was
the need to incorporate, within asthma review, an assessment of patient perspectives including their goals and aspirations
and to elicit their beliefs and concerns about asthma and its treatment. This can be used as a basis for agreement between
the healthcare professional and patient on a predefined target regarding asthma control and a treatment plan to achieve
this.
Summary: Optimum review of asthma is essential to improve control. A key priority is the development of simple and
effective tools for identifying poor control for individual patients coupled with a tailored approach to treatment to enable
patients to set and achieve realistic goals for asthma control.
Background
Asthma is a chronic inflammatory disease of the airways,
resulting in widespread but variable airflow obstruction in
response to a variety of stimuli[1]. Airflow obstruction is
usually reversible, either spontaneously or with treatment,
though remodelling may lead to irreversible structural
changes.
National and international guidelines clearly state that the
aim of asthma management is to achieve and maintain
control[1,2]. Controlled asthma is characterised by mini-
mal or no symptoms during the day and at night, no
asthma attacks, no emergency visits to physicians or hos-
pitals, minimal need for reliever medications, no limita-
tions on physical activities and exercise, nearly normal
lung function and minimal or no side-effects from medi-
cation.
With the medical treatments currently available, it is pos-
sible to achieve control in the majority of patients with
asthma, at least in the artificial setting of a clinical trial[3].
However, in the real world where patients make choices
that may reflect conflicting priorities, asthma still imposes
a considerable burden on healthcare systems, largely as a
result of poor control.
There is evidence, from a 10 year Finish study, that
enhancing the delivery of healthcare services, can improve
asthma control[4] but, in most countries, poor control
remains a significant burden for patients and the health-
care system. An analysis of nine studies conducted in Aus-
tralia, Canada, France, Sweden, UK and USA showed that
around one third of the direct costs of asthma, and three-
quarters of the total costs of asthma, were a consequence
of uncontrolled disease[5]. In a US study conducted in
1993, the average cost per patient ranged from US$47 for
those with controlled disease, to US$7030 for those with
uncontrolled symptoms[6]. A survey in the UK found that
the annual cost of a patient who experienced an asthma
exacerbation (indicative of uncontrolled asthma) was
more than 3.5 times the cost of those who did not experi-
ence an attack (£381 vs. £108)[7]. International studies
have confirmed the high cost of managing exacerba-
tions[8,9].
There are many possible reasons for poor control (Table
1). However, regardless of the underlying causes, the level
of control achieved reflects the behaviour of both health-
care professionals and patients (Figure 1)[10]. Healthcare
professionals need to conduct asthma reviews and take
appropriate action if control is poor. Patients need to
engage in self-management behaviours with optimal
adherence to appropriate treatment. Differences in the
perspectives of patients and healthcare professionals
could affect their behaviours and consequently the
achievement of asthma control. It may be possible for
healthcare professionals to improve asthma control by
achieving a greater understanding of the patient's perspec-
tive.
These issues are of particular relevance in primary care,
where the majority of patients with asthma are managed.
An international panel of general practitioners, respira-
tory physicians, patient representatives and others with an
interest in asthma control, under the auspices of the Inter-
national Primary Care Respiratory Group (IPCRG), con-
sidered the evidence about patient perspectives and
discussed the resulting implications. This report summa-
rises the discussion.
Discussion
Presentations by group members on different aspects of
asthma control resulted in a wide ranging discussion that
crystallised around three key questions.
1. What levels of asthma control are patients currently
achieving?BMC Pulmonary Medicine 2007, 7:8 http://www.biomedcentral.com/1471-2466/7/8
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2. What are the common causes of poor control?
3. What are the main patient-related determinants of
asthma control?
Each of these questions is addressed, below.
1 – What levels of asthma control are patients currently 
achieving?
Large population-based studies, varying in methodology
and funding, suggest that a substantial proportion of
patients with asthma currently experience suboptimal lev-
els of asthma control. The AIRE (Asthma Insights and
Reality in Europe) study, involving over 2,800 people
with asthma in France, Germany, Italy, Netherlands,
Spain, Sweden and UK, found that asthma symptoms are
part of everyday life for many patients[11]. More than half
(56%) of the respondents (identified by telephone inter-
views of randomly selected households) suffered daytime
symptoms in the last 4 weeks, and around one in three
respondents experienced sleep disruption due to asthma
at least once a week. Among the 753 children (<16 years)
surveyed, 28% suffered night time symptoms in the previ-
ous month, with 61% needing to use their rescue medica-
tion.
Findings consistent with the AIRE study have been
reported from the INSPIRE (INternational aSthma Patient
Insight REsearch) study[12]. This study, conducted in
eleven countries (Australia, Belgium, Canada, France, Ger-
many, Italy, Netherlands, Spain, Sweden, UK, USA),
included 3,415 adults with asthma treated with inhaled
corticosteroids, recruited via their physicians and inter-
viewed by telephone. Nearly three-quarters of the patients
(74%) used a short-acting bronchodilator every day and
half of all patients (51%) had at least one exacerbation
requiring medical intervention in the past year. The mean
number of asthma worsenings was 16 in those patients
with uncontrolled asthma, compared with 6 in patients
with well-controlled asthma.
2 – What are the common causes of poor control?
There are many reasons why asthma may be poorly con-
trolled, both clinical and behavioural. Important clinical
factors include the genetic characteristics of the individ-
ual, type of asthma (e.g. aspirin-sensitivity, neutrophilic
activity), co-morbidity (e.g. dysfunctional breathing,
allergic rhinitis)[13,14]. The behaviour of both clinicians
and patients is also an important determinant of the level
of asthma control achieved.
The behaviour of clinicians is vital in making an accurate
diagnosis and prescribing the best treatment but also in
carrying out appropriate review of progress and subse-
quent control[15]. Healthcare professionals may have
limited awareness of symptom prevalence. In the AIR
(Asthma in Real life) study, general practitioners substan-
Patient and healthcare professional behaviour affects asthma  control [10] Figure 1
Patient and healthcare professional behaviour affects asthma 
control [10].
Effective treatments
Optimum outcomes
Behaviour
Practitioner: 
prescribing
Patient: 
medicine-taking
Table 1: Reasons for poor control
Co-morbidity (e.g. rhinitis, COPD)
Severe therapy-resistant disease
Ongoing exposure to triggers (e.g. occupational asthma, pets, mite etc)
Inadequate assessment
Misdiagnosis
Inadequate treatment
Ineffective delivery of treatment (e.g. poor inhaler technique)
Limited treatment effectiveness (e.g. smoking interfering with steroid actions)
Inadequate use of action plans
Low patient and physician expectations
Low adherence with agreed asthma therapy
Functional and psychological problems affecting willingness to use therapy
Over-reliance on complementary/alternative treatment
Not attending medical consultations
Patients do not perceive symptoms as indicative of poor controlBMC Pulmonary Medicine 2007, 7:8 http://www.biomedcentral.com/1471-2466/7/8
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tially underestimated the prevalence of asthma symptoms
(Figure 2)[16]. Furthermore, healthcare professionals
may have difficulties estimating levels of asthma con-
trol[17,18]. Clearly, there is a need for healthcare profes-
sionals to appreciate the widespread occurrence of poor
asthma control.
Patient behaviours are also key as the level of asthma con-
trol is influenced by adherence to treatment and other
self-management behaviours[19] and smoking[20].
Patients' may also fail to consult their doctor. A UK survey
found that 10% of asthmatic patients had seen no health
professional about asthma in the previous 3 years[21].
3 – What are the main patient-related determinants of 
asthma control?
Patient expectations, aspirations and goals
Patients may unnecessarily accept symptoms, assuming
that frequent symptoms, exacerbations and lifestyle limi-
tations are an inevitable consequence of having
asthma[22]. In the AIRE study, the majority of patients
considered themselves to have controlled asthma, yet
symptom levels showed control failing to reach the levels
expected by management guidelines[11]. Patients may
not realise that effective treatments are available. This was
demonstrated in a study of 517 patients in the UK[23].
While 58% of patients reported that they were very satis-
fied with the standard of their asthma management, this
fell to 33% after being shown the standards that patients
can expect, as detailed in international guidelines. Such
work implies that there is a need to raise patient expecta-
tions by increasing awareness of the quality of life that
could be attained.
What level of control do patients want to achieve?
When asked about the things that they most dislike about
asthma, patients most report symptoms such as cough,
breathlessness, and lifestyle restrictions[16]. In a study of
patients with asthma, 55% of respondents reported that
they would find a written action plan helpful[23], though
another study reported that 45% of patients neither had
nor wanted regular asthma review[15]. Some of the goals
that patients say they want are apparently contradictory
(e.g. they may want few symptoms and no impact on
activities, but do not want to take medication that could
help achieve this). In real life, patients make choices
between different attributes of the disease and its treat-
ment, trading off one aspect for another – just as they may
choose between consumer goods that offer different fea-
tures at different costs. Discrete choice experiments allow
integration of these different aspects in one measure by
presenting patients with a choice of scenarios, each of
which includes the key characteristics at different levels.
Health technology assessment agencies, such as NICE,
may use information from discrete choice experiments to
understand the issues that matter to patients[24].
A discrete choice experiment showed that patients were
willing to experience higher levels of wheeze and sleep
disturbance to avoid cough and breathlessness [25]. How-
ever, patients who have not experienced an exacerbation
may not rate avoidance of an attack as highly as those who
have suffered one, possibly because of the pronounced
impact of an exacerbation on quality of life[26]. Discrete
choice experiments have also been used to assess patient
preference for different treatment regimens[27] and for
autonomy in decision-making in asthma manage-
ment[28].
Patient goals and asthma control
Currently, asthma control is measured in ways defined by
healthcare professionals (e.g. use of reliever medication,
lung function, need for unscheduled healthcare). How-
ever, these standard methods use surrogate markers that
do not seem to be necessarily relevant to the individual
patient. In contrast, psychological treatments routinely
use patient-defined goals, achievement of which can be
seen by both patient and healthcare professional as mark-
ers of improvement. For example, an agoraphobic patient
may set a goal of walking to the shop to buy a newspaper
each day. Identifying and using patient goals has been
shown to encourage patient involvement, which may lead
to better adherence with therapy[29]. It is also consistent
with the view that effective therapy is that which satisfies
the patient's goals and expectations[30].
Few published studies have explored this issue in asthma
with the exception of two recent studies. In the first
study[31] in 329 adults with asthma, patients were asked
Healthcare professional and patient perspectives of the  occurrence of asthma symptoms [16] Figure 2
Healthcare professional and patient perspectives of the 
occurrence of asthma symptoms [16].
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to name up to three personal goals, achievement of which
would indicate to them that their asthma treatment was
effective. One year later, patients were asked to score the
extent to which they had achieved their goals. Most
patients (92%) were able to set three goals. Themes from
patient-named goals were categorised qualitatively, sub-
ject to inter-rater reliability, with key words identified for
each theme. Four main themes were identified: reducing
activity limitation (named by 60% of participants), reduc-
ing asthma symptoms (named by 52% of patients), avoid-
ing/reducing exacerbations (named by 46% of patients),
and 38% wished to reduce their use of relief treatment.
Within these themes, patients could name more specific
behavioural goals (e.g. avoiding use of out-of-hours serv-
ice, being able to play more sport). Patient-set goals
appeared to be responsive to change. When asked to score
the achievement of their goals at the end of the study, 49%
of participants considered that they had achieved or par-
tially achieved their own goals of treatment.
In the second study of 83 patients with exercise-induced
asthma treated using montelukast or placebo, patients
were also able to set their own goals[32]. The nature of
these goals was very similar to that found previously, fall-
ing into four themes of reducing activity limitations,
asthma symptoms, exacerbations and use of medication.
These were more sensitive to change than the responses to
the Royal College of Physicians' three questions[33].
Patient adherence to treatment and other aspects of self-
management
Patients may not take the medications they have been pre-
scribed, contributing to poor disease control. Regardless
of age, gender and socioeconomic status of patients, and
type and severity of disease, non-adherence rates of over
30% have consistently been noted across chronic ill-
nesses[34] and with even higher rates of nonadherence to
inhaled corticosteroids[35]. Non-adherence may be lower
for more complex regimens, but significant non-adher-
ence remains even when the frequency of dosing is
reduced[36,37]. Furthermore, providing clear informa-
tion – although essential – is not enough to guarantee
adherence[38].
Nonadherence is best thought of as a variable behaviour,
rather than a trait characteristic: most people are nonad-
herent some of the time. Nonadherence can have both
intentional and unintentional causes. Unintentional non-
adherence arises from capacity and resource limitations
that prevent patients from implementing their decisions
to follow treatment recommendations and involves indi-
vidual constraints (e.g. poor inhaler technique, problems
remembering doses etc) and aspects of their environment
(e.g. problems of accessing prescriptions, cost, competing
demands etc). Intentional nonadherence arises from the
beliefs, attitudes and expectations that influence patients'
motivation to begin and persist with the treatment regi-
men[37].
Patients' 'common-sense' beliefs about treatment and perceptions of 
asthma
Patients' self-management of their asthma is strongly
influenced by their 'common-sense' beliefs about illness
and treatment[39]. Patients do not blindly follow treat-
ment advice even when it comes from trusted parishion-
ers. Rather they evaluate whether the advice makes
common sense in the light of their own understanding
and beliefs about the illness and treatment [40]. Patients'
adherence to medication is particularly influenced by the
way in which they evaluate their personal need for medi-
cation relative to their concerns about potential negative
effects of taking it. The utility of this simple necessity-con-
cerns framework in explaining nonadherence has been
shown in studies across a range of chronic illnesses [41-
43], including asthma[44].
Patients are more likely to doubt the necessity of treat-
ment if they do not perceive a good fit with their com-
mon-sense understanding of their illness and symptoms
experiences relative to expectations[45,46]. A study of
adherence to ICS in community-managed asthma
patients in the UK showed that for many patients, the
medical model of asthma as a chronic condition requiring
daily preventer treatment was perceived to be at odds with
their symptomatic experience of asthma as an episodic
condition (e.g. my asthma isn't there when I don't have
symptoms). These patients were more likely to doubt
their personal need for daily ICS and were significantly
less adherent[45]. Moreover, patients' concerns about
potential adverse effects of medication become more sali-
ent when they doubt the necessity of treatment[40].
Patients' concerns about prescribed treatment extend
beyond the experience of side effects to include more
abstract worries arising from negative beliefs about phar-
maceuticals such as the potential for dependence and
long-term effects[47].
Mistrust of orthodox therapies may be one reason why
many patients resort to unproven complimentary or alter-
native treatments for asthma. Surveys have shown high
levels of use of such treatments by asthmatics in spite of a
poor evidence base for efficacy[48].
Patients' beliefs about asthma and its treatment may be a
hidden determinant of nonadherence when they are not
volunteered in the consultation. If healthcare profession-
als are not aware of patient beliefs and hold different
(sometimes opposing) beliefs about the nature of the ill-
ness and its appropriate treatment, then the consultation
is unlikely to lead to successful outcomes. Where peopleBMC Pulmonary Medicine 2007, 7:8 http://www.biomedcentral.com/1471-2466/7/8
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lack information they may have inaccurate and unin-
formed views on the illness. They may also ignore missing
information, devalue a treatment option, or make infer-
ences based on the limited information they do have.
Although patient beliefs govern their attitudes towards
therapy, these beliefs are not fixed and can be changed
through education and negotiation[49]. Finally, other
psychological factors such as anxiety and depression may
influence patient behaviour and asthma control[50]. Soci-
oeconomic status[51] and ethnicity[52] are also impor-
tant.
Implications for practice
Three implications for health care professionals emerged
from the debate on the patient's perspective of asthma
control. The need
1. For simple tools to assess and monitor asthma control;
2. To identify the patient-related reasons for poor control;
3. To incorporate patient perspectives into the routine
review of asthma in primary care
Each of these implications is discussed in turn, below.
1 – Assessing and monitoring asthma control
Severity vs. control
Management guidelines for asthma, as with many other
diseases, include treatment algorithms based on severity
of disease, as defined by the clinical features before treat-
ment or by the treatment given[1,2]. Severity usually
refers to the degree of underlying pathology. Deciding the
severity of asthma is not always easy[53]. When respira-
tory specialists were shown a number of case studies and
asked to assign the severity of the asthma for each case,
there was considerable disagreement[54]. The inherent
variability of asthma also presents problems for classifica-
tion of severity[55]. Severe asthma, defined as persisting
symptoms despite high levels of treatment, is likely to
have a number of underlying reasons, including psycho-
logical and adherence factors[56].
Although the factors indicating control may be the same
as those indicating severity (e.g. persistent symptoms,
impaired lung function, high bronchodilator use, oral
steroid use, unscheduled consultations, hospitalisations,
life-threatening attacks), there is a difference in the two
concepts. Patients with severe asthma can be well-control-
led, while those with mild underlying disease can show
signs of poorly controlled disease. Changing the manage-
ment plan to one based on control and the goals of
patients may show improved outcomes compared to a
plan based on severity.
Hospital-based studies have suggested that outcomes may
be better with treatment algorithms based on parameters
that are more closely linked to control than usual symp-
tom-based management protocols. There is a reduction in
exacerbation rate, although a higher inhaled corticoster-
oid load received, in patients given treatments that opti-
mise reduction in bronchial hyperreactivity, rather than
treatment on the basis of symptoms[57]. Likewise, a treat-
ment strategy based on normalisation of sputum eosi-
nophil levels resulted in reduced exacerbations compared
to standard management protocols, without increasing
steroid exposure[58]. A randomised controlled trial con-
ducted in New Zealand used a management strategy
incorporating exhaled nitric oxide (NO) readings and
achieved control that was at least as good as that obtained
with a guideline-based approach but using a lower
inhaled steroid dosage[59]. The GOAL study used a strat-
egy based on the combined aims of treatment given in the
GINA guidelines[1], and showed that the majority of
patients treated with individually titrated doses of inhaled
corticosteroids, either alone or in combination with long-
acting beta2-agonist, could achieve and maintain control.
The need for simple valid and reliable measures of asthma control
In many chronic diseases, healthcare professionals have a
philosophy of treating to achieve a predefined target level
in a surrogate marker that indicates good control How-
ever, in asthma, there is currently no simple, clear,
accepted target measure that healthcare professionals can
aim to achieve, and that patients can use as a reliable indi-
cator of treatment effectiveness. Instead, asthma control is
currently implied in a number of ways (Table 2).
Assessment of asthma has traditionally been based on
parameters noted in management guidelines, such as lung
Table 2: Current methods used to imply level of asthma control
Measure Comments
Symptoms Day, night, exercise-induced
Lung function % predicted, % variability
Healthcare resource use Rescue medication, oral steroids, emergency consultations, hospitalisation
Bronchial hyperreactivity Not suitable for routine clinical use
Biomarkers Sputum eosinophils, exhaled NO
Health status Numerous questionnaires availableBMC Pulmonary Medicine 2007, 7:8 http://www.biomedcentral.com/1471-2466/7/8
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function and symptoms. However, there is little correla-
tion between commonly measured objective measure-
ment of lung function using peak flow meters or
spirometry and the level of symptoms or quality of life
impairment perceived by patients[60], and less easily
measured parameters such as lung hyper-inflation may
show better correlations with symptoms such as breath-
lessness[61]. This may be due, in part, to other factors that
influence perception of symptoms, such as concomitant
anxiety, depression and socioeconomic status[51]. The
demonstration of variability and reversibility of airflow
limitation confirms asthma but the absence of these fea-
tures at a given moment in time does not preclude the
diagnosis.
A simple tool is required to assess asthma control accu-
rately. The tool needs to be quick to use in primary care,
where the majority of patients with asthma are managed
by a range of healthcare professionals, in brief consulta-
tions. The ideal features of an asthma control tool are
summarised in Table 3. Two approaches can be consid-
ered: monitoring of biometric markers of control and
development of questionnaires to record patient-reported
outcomes.
Biometric markers assess factors associated with the
pathogenesis of asthma. The definition of asthma encom-
passes airways hyperresponsiveness and inflammation,
which may both be more closely linked to asthma control
than traditional measures of symptoms and lung func-
tion. Measurements of bronchial hyperreactivity have
higher sensitivity and specificity for the diagnosis of
asthma than measurements of diurnal variation in peak
flow[62,63]. Exacerbations occur more frequently in
patients with high bronchial reactivity, compared with
those with reduced bronchial reactivity, though there is
poor correlation between bronchial hyperreactivity and
markers of inflammation. Bronchial hyperreactivity can
be assessed by direct challenge (e.g. inhalation of hista-
mine or methacholine) or indirectly (e.g. using exercise,
or inhalation of hypertonic saline or mannitol). However,
measurements of bronchial hyperreactivity are time con-
suming, and require appropriate equipment and health-
care professional expertise as well as patient cooperation,
limiting the value of the approach as a practical measure
of control. There is some interest in the use of mannitol
BHR but this approach has yet to be fully evaluated in pri-
mary care.
Inflammation is central to the pathogenesis of asthma,
with anti-inflammatory treatment forming the basis of
asthma management. New technological developments
enable non-invasive measurement of inflammation. Eosi-
nophil count estimations in spontaneously produced or
induced sputum can be measured as a marker of control,
though the method requires appropriate expertise and
laboratory support so is not currently suitable for use in
routine primary care. Another surrogate measure of
inflammation is exhaled nitric oxide (NO). NO is pro-
duced in low levels by airways epithelial and endothelial
cells, but inflammatory cells contribute to greatly
increased levels, explaining the observed correlation
between NO-levels and eosinophilic inflammation[64].
Until recently, exhaled NO estimations necessitated the
use of expensive monitoring equipment restricted to sec-
ondary care and research settings. However, technological
advances have resulted in the development of inexpen-
sive, handheld monitors to record exhaled NO, which are
potentially available for use in primary care. This biomet-
ric method for assessment of control has some promise
and is currently being evaluated.
Patient-based outcome measures
Patient-based outcome measures (Table 4)[65] may be
useful to assess asthma control. A number of such tools
have been developed that involve questioning the patient
about outcomes achieved. Such tools may be generic or
disease specific. Generic measures, such as the EQ-
5D[66], are often easy to use, brief and acceptable to both
patients and practitioners. They also capture the impact of
comorbid conditions (which are common in patients
with asthma) and allow comparison across patient groups
and therapies. However, asthma-specific outcome meas-
ures are more sensitive than generic measures to disease-
specific aspects of health-related quality of life and the
effects of asthma treatments.
There are a number of asthma-specific patient-based
measures available that vary in characteristics, technical
validity and ease of use. The Rule of Two™ consists of three
items covering asthma symptoms and rescue medication
use, each of which is answered with 'yes' (= 2 points) or
Table 3: Ideal features of a tool to assess asthma control
Convenient to perform
Objective measure of asthma control
Simple Numeric value
Give a clear Target to guide treatment
Reliable, valid and responsive to changes in asthma control over time
Able to predict Outcomes
Complementary to Lung function testsBMC Pulmonary Medicine 2007, 7:8 http://www.biomedcentral.com/1471-2466/7/8
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'no' (= 1 point) so that summing the answers gives a score
ranging from 3 (= poor control) to 6 (= good control)[67].
Although some validation of the instrument has been car-
ried out, there is no information on a minimal important
difference and limited data on responsiveness. However,
the instrument is quick and easy to use in consultations.
The 30-second test is widely used in Canada, where it is
recommended in management guidelines[68]. Although
the six questions are easy and quick to answer with yes/
no, responsiveness has not been determined. The Royal
College of Physicians three questions are validated against
other tools, widely used in the UK and recommended in
management guidelines[33]. With the questions requir-
ing simple yes/no answers, the method is quick and easy
to use in clinical practice. Tools such as the Asthma Con-
trol Test™ (ACT)[69,70], and the Asthma Control Ques-
tionnaire™ (ACQ)[71,72] are also useful, and show good
correlation with each other [53,73]. The ACT is shorter,
requires no calculations and includes a question on the
patient's view of control so gives a useful insight into the
patient perspective. Both the ACT and ACQ are validated
tools that are reliable and responsive to changes in asthma
control over time, and provide a single numerical indica-
tion of control that has the potential to provide a target to
drive management, analogous to that of a blood pressure
measurement or a lipid measurement for management of
hypertension or dyslipidaemia. Both measures have the
potential to influence long-term asthma outcomes, rais-
ing expectations for asthma management and facilitating
the achievement of asthma control.
2 – Identifying and addressing patient-related reasons for 
poor control
Identifying poor asthma control is the first step in improv-
ing it. The next step is to establish the reasons for poor
control in individual patients. This should include an
assessment of whether patient behaviours such as smok-
ing or treatment nonadherence might be contributory fac-
tors. Patients may be reluctant to admit smoking or
nonadherence if they believe that this will offend the cli-
nician. However, asking adherence questions in a sup-
portive manner, which sanctions nonadherence, can
overcome this problem leading to more accurate
reports[45].
It is also important to identify the specific reasons for non-
adherence in individual patients. One of the reasons why
previous interventions to improve adherence have met
with limited success[74] is that they have taken a 'one-size
fits all' approach, rather than individualising the
approach to meet the specific needs of the patient[37].
Interventions to facilitate optimum adherence with
asthma therapy are likely to be more effective if they are
individualised and address perceptual barriers (e.g.
patient beliefs and expectations) as well as practical barri-
ers (e.g. regimen convenience, ability to use inhaler
devices)[45].
Healthcare professionals can provide information about
illness and treatment. However, unless the information
given has an impact on patients' common-sense beliefs
about the illness and treatment, it will not change patient
behaviour. Healthcare professionals should ask about cur-
rent illness and treatment beliefs. Although patient beliefs
govern attitudes towards therapy, these beliefs are not
fixed and can be changed through education and negotia-
tion, leading to a better understanding of asthma that may
promote more effective self-care behaviours[45]. In short,
what people believe about their asthma may affect how
they cope with it, and tailored education is the first stage.
A three-step approach, covering perceptions and practical-
ities, has been suggested to facilitate optimal adherence to
appropriately prescribed treatment[75]. This suggests that
healthcare professionals should:
1) provide a common-sense rationale for the necessity of
treatment that is consistent with the patient's common-
sense model of asthma and their goals for asthma control
2) elicit and address specific concerns about treatment
Table 4: Criteria for selecting patient-based outcome measures [65]
Criteria Comments
Appropriateness Match to the specific purpose and question to be addressed
Reliability Reproducible and internally consistent
Validity Measures what it purports to measure
Responsiveness Sensitivity to changes of importance to patients
Precision Number and accuracy of distinctions made by the instrument
Interpretability How meaningful the scores are
Acceptability How acceptable to the respondents
Feasibility Effort, burden and disruption to staff and clinical careBMC Pulmonary Medicine 2007, 7:8 http://www.biomedcentral.com/1471-2466/7/8
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3) prescribe a convenient treatment regimen tailored to
address practical barriers to adherence (e.g. correct inhaler
technique, use of combination inhalers to reduce inhaler
load (if indicated)).
Identifying and addressing misplaced health beliefs (e.g.
asthma is an episodic disease) may be helped by tailoring
education to the patient's own needs and goals. Explicitly
eliciting patient goals and using these as a basis for treat-
ment and education may allow professionals to identify
more effectively what is important to the patient and
allow the patient to assess meaningful changes in their
asthma. The importance of the patient in their own self-
care is increasingly recognised, with development of initi-
atives to support self-care[76]. Teaching physicians to
improve interactions with patients can result in greater
ability to address patients' fears about asthma medication
and improvement in asthma control[77].
3 – Incorporating patient perspectives into the routine 
review of asthma in primary care
The identification of non-adherence as a cause of poor
control, and the factors contributing to poor adherence,
has increased recognition of the need for individual
patient-centred reviews. However, there are increasing
resource constraints in primary care. Currently, asthma
reviews are often not standardised in structure and data
collection, are not comprehensive, fail to address the
needs and expectations of patients, are ineffective at
reducing morbidity and mortality, and are poorly
attended.
The Minimal Asthma Assessment Tool (MAAT) is under
development as a method to address some of these issues,
and to help prioritise patients for primary care review by
identifying poor asthma control and the causes of poor
control for individual patients[78]. The MAAT consists of
a brief 2-page questionnaire covering patient views about
preventer inhalers, actual use and perceived side-effects,
how asthma affects the individual, and issues likely to
affect asthma control such as smoking and co-morbid
rhinitis. An international study is planned to evaluate use
of the MAAT. The development of effective tools to facili-
tate more efficient, patient-centred review of asthma in
primary care is vital to improving asthma control and
patient quality of life.
Summary
It is possible to improve current levels of asthma control
if healthcare professionals do four things:
1) use appropriate, patient-centred tools to assess control
2) identify the reasons for poor control in individual
patients
3) work with patients to design individual treatment plans
that address poor control and the causes of poor control,
taking account of patient goals and aspirations
4) monitor outcomes and take appropriate action through
regular review
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